Roche Diagnostics has launched the CE IVD approved Cobas 4800, a high-speed analyser for testing Chlamydia/ Neisseria Gonorrhoeae (CT/NG) and also for the Human Papillomavirus (HPV).
The company said that the instrument is user-friendly and offers high throughput and efficiency.
The HPV test performed on the Cobas 4800 has a high negative predictive value, providing more information for clinicians in the fight against cervical cancer.
The instrument features fully automated swab and urine sample preparation and combines with real-time PCR technology for amplification and detection, plus easy-to-use software that integrates into both extraction and amplification components.
Its streamlined workflow and throughput flexibility means that up to 376 CT/NG or 282 HPV samples can be run in a day.
Less intensive testing needs can also be accommodated.
Prof Paul Savelkoul of VU University Medical Center, Molecular Microbiology, Amsterdam, who undertook a comparison study of the Cobas 4800 CT/NG test commented that the instrument was 'very promising' and that both the CT and the NG test showed 'a high sensitivity and specificity'.
